14 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 32181767 | [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors]. | 2020 Mar 17 | 1 |
2 | 32336014 | RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors. | 2020 Aug | 1 |
3 | 30846494 | Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. | 2019 Oct | 2 |
4 | 28424891 | A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. | 2017 Oct | 3 |
5 | 28620782 | Role of key genetic mutations on increasing migration of brain cancer cells through confinement. | 2017 Sep | 1 |
6 | 26802155 | Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. | 2016 Apr | 3 |
7 | 25933683 | Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. | 2015 Jul | 1 |
8 | 26250606 | Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer. | 2015 Nov | 1 |
9 | 25199829 | RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. | 2014 Sep 11 | 1 |
10 | 23414467 | Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. | 2013 Feb | 1 |
11 | 23372439 | (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. | 2012 May | 3 |
12 | 21910575 | Inhibitor of MEK1/2, selumetinib, for biliary tract cancer. | 2011 Oct | 1 |
13 | 20587667 | Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. | 2010 Jul | 1 |
14 | 18676837 | BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. | 2008 Aug 1 | 1 |